Scholars Central

Conference abstractPublished 24 Sep 2018

Metformin prevents high glucose induced disruption of coronary artery endothelial barrier function and accelerates wound healing

Authors: Mohammad Tauseef, Ravi Patel, Chand Yadav, Mohd Shahid, Hafeez Faridi, Mohammad Newaz

Chicago State University, Chicago

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Despite the great strides have been made in treating hyperglycemia-induced vascular endothelial barrier dysfunction, current treatments have shown limited success in reversing vascular pathologies. During inflammatory conditions, such as diabetes mellitus, endothelial cell-cell junctions start to disrupt because of the internalization of the junctional proteins, such as Vascular Endothelial (VE) cadherin. This leads to the formation of minute inter-endothelial gaps, and the infiltration of protein-rich fluid and immune cells in the interstitial space. If remaining unchecked, the persistent buildup of edema underlying the endothelial lining sets the stage for the serious life-threatening complications. Wound healing impairment is also increasingly recognized to be a consequence of hyperglycemia-induced dysfunction of endothelium in type 2 diabetes mellitus (T2DM). Metformin, an oral antihyperglycemic agent, is the first line drug in the clinic for patients with T2DM. We hypothesized that the metformin prevents high glucose-induced endothelial barrier dysfunction and accelerates the wound healing process in human coronary endothelial cells (HCAE) via preventing the destabilization of junctional protein, VEcadherin. Endothelial permeability and wound healing process were evaluated by using state of the art Electric Cell-Substrate Impedance Sensing (ECIS) mechanism. Our data show that high glucose concentration increased endothelial permeability and abrogated the wound healing process. Metformin significantly prevented the alteration of endothelial barrier function and enhances the wound healing process. Metformin also prevented Myosin Light Chain Kinase (MYLK) phosphorylation and increased in VE-cadherin expression in presence of high glucose concentration in HCAE. In conclusion, metformin is emerging as a potential therapeutic treatment for improving endothelial barrier function to prevent and treat coronary artery disease in diabetes mellitus.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Clinical Trials.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Clinical Trials
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Mohammad Tauseef”
  • BylineArticles whose byline prints “Ravi Patel”
  • BylineArticles whose byline prints “Chand Yadav”
  • BylineArticles whose byline prints “Mohd Shahid”
  • BylineArticles whose byline prints “Hafeez Faridi”
  • BylineArticles whose byline prints “Mohammad Newaz”